Page last updated: 2024-11-04

pyridoxamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Pyridoxamine is a vitamin B6 analog that has been studied for its potential therapeutic benefits in a variety of conditions, including diabetes, Alzheimer's disease, and cancer. It is synthesized from pyridoxal, the active form of vitamin B6, by reduction with sodium borohydride. Pyridoxamine is known to have anti-inflammatory, antioxidant, and neuroprotective effects. It is also believed to improve insulin sensitivity and reduce the risk of developing type 2 diabetes. Pyridoxamine has been shown to inhibit the formation of advanced glycation end products (AGEs), which are implicated in the pathogenesis of various chronic diseases. Research on pyridoxamine continues to explore its potential as a therapeutic agent, especially in the areas of metabolic diseases, neurodegenerative disorders, and age-related conditions.'

Cross-References

ID SourceID
PubMed CID1052
CHEMBL ID593019
CHEBI ID16410
SCHEMBL ID30408
MeSH IDM0018243

Synonyms (57)

Synonym
EU-0067145 ,
BB 0260463
CHEBI:16410 ,
4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol
NSC21278 ,
3-pyridinemethanol, 4-(aminomethyl)-5-hydroxy-6-methyl-
NCI60_001792 ,
nsc-21278
4-(aminomethyl)-5-(hydroxymethyl)-2-methyl-3-pyridinol
CBDIVE_013510 ,
einecs 201-640-5
4-(aminomethyl)-3-hydroxy-2-methyl-5-pyridinemethanol
2-methylpyridin-3-ol-5-(hydroxymethyl)-2-methylpyridin-3-ol
NCGC00013273 ,
OPREA1_400404 ,
pxm ,
85-87-0
PYRIDOXAMINE ,
C00534 ,
NCI21278 ,
NCISTRUC2_000537 ,
NCISTRUC1_000457 ,
LS-187660 ,
LS-187048 ,
NCGC00096392-01
NCHEMBIO.93-COMP3 ,
STK503617
48DD06CB-7B30-4F04-8D74-6F84BDBF5AA9
AKOS000264716
BMSE000130
pyridoxylamine
CHEMBL593019
CCG-38056
NCGC00013273-02
6466nm3w93 ,
unii-6466nm3w93
4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol dihydrochloride hydrate
SCHEMBL30408
pyridoxamine [mi]
pyridoxamine [who-dd]
DTXSID6046929
4-(aminomethyl)-5-(hydroxymethyl)-2-methyl-3-pyridinol #
3-pyridinol, 2-methyl-4-aminomethyl-5-hydroxymethyl-
mfcd00464815
SR-01000392002-1
sr-01000392002
GS-3241
4-(aminomethyl)-5-hydroxy-6-methyl-3-pyridinemethanol
2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol
HY-B1745
CS-0013764
DB11673
Q2541149
A936529
F82068
4-aminomethyl-5-hydroxy-6-methyl-3-pyridinemethanol
EN300-254254

Research Excerpts

Overview

Pyridoxamine (PM) is a structural analog of vitamin B6 that interferes with oxidative macromolecular damage via a number of different mechanisms. It is in a phase 3 clinical efficacy trial to delay CKD progression in patients with diabetic kidney disease.

ExcerptReferenceRelevance
"Pyridoxamine (PM) is a promising drug candidate for treating various chronic conditions/diseases in which oxidative stress and carbonyl compounds are important factors affecting pathogenicity. "( Inhibition effect of pyridoxamine on lipid hydroperoxide-derived modifications to human serum albumin.
Lee, SH; Matsunaga, A; Oe, T, 2018
)
2.24
"Pyridoxamine is a derivate of vitamin B6, which has been shown to reduce AGE formation."( Pyridoxamine reverts methylglyoxal-induced impairment of survival pathways during heart ischemia.
Almeida, F; Crisóstomo, J; Gonçalves, L; Matafome, P; Rodrigues, T; Santos-Silva, D; Seiça, R; Sena, C, 2013
)
2.55
"Pyridoxamine (PM) is a prospective drug for the treatment of diabetic complications. "( 5'-O-Alkylpyridoxamines: Lipophilic Analogues of Pyridoxamine Are Potent Scavengers of 1,2-Dicarbonyls.
Amarnath, K; Amarnath, V; Avance, J; Stec, DF; Voziyan, P, 2015
)
2.26
"Pyridoxamine (PM) is a structural analog of vitamin B6 that interferes with oxidative macromolecular damage via a number of different mechanisms and is in a phase 3 clinical efficacy trial to delay CKD progression in patients with diabetic kidney disease."( Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury.
de Caestecker, CR; de Caestecker, MP; Drouin, M; Harris, RC; Hudson, B; Skrypnyk, NI; Theberge, MC; Voziyan, P; Yang, H, 2016
)
2.6
"Pyridoxamine is a vitamin B(6) derivative involved in biological reactions such as transamination, and can also act as inhibitor in protein glycation. "( Unexpected isomeric equilibrium in pyridoxamine Schiff bases.
Adrover, M; Donoso, J; Muñoz, F; Vilanova, B, 2009
)
2.07
"Pyridoxamine (PM) is an effective inhibitor of the formation of the carcinogen acrylamide (AA) from its precursors in low-moisture model systems. "( Isolation and structural characterization of acrylamide-pyridoxamine adducts.
Arribas-Lorenzo, G; Morales, FJ; Pintado-Sierra, M, 2011
)
2.06
"Pyridoxamine is an inhibitor of advanced glycation end-product (AGE) formation derived from vitamin B(6)."( The next generation of diabetic nephropathy therapies: an update.
Tuttle, KR; Williams, ME, 2005
)
1.05
"Pyridoxamine is a post-Amadori AGE inhibitor-that is, an "Amadorin"-whereas aminoguanidine primarily scavenges reactive dicarbonyl precursors to AGEs."( Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Chen, Y; Khalifah, RG; Wassenberg, JJ, 2005
)
1.05
"Pyridoxamine is an efficient AGE inhibitor in experimental diabetes."( New potential agents in treating diabetic kidney disease: the fourth act.
Williams, ME, 2006
)
1.06
"Pyridoxamine (PM) is a promising drug candidate for treatment of diabetic nephropathy. "( Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.
Chetyrkin, SV; Hudson, BG; Serianni, AS; Voziyan, PA; Zhang, W, 2008
)
3.23
"Pyridoxamine is a potent drug against protein glycation, and can act on several pathways in the glycation process."( The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect.
Adrover, M; Donoso, J; Frau, J; Muñoz, F; Vilanova, B, 2008
)
1.63

Effects

Pyridoxamine (PM) has long been known to inhibit protein glycation via various mechanisms of action. PM has been reported to protect renal tubular epithelial cells against oxidative damage and delay the development of glucose-induced renal insufficiency.

ExcerptReferenceRelevance
"Pyridoxamine (PM) has been reported to protect renal tubular epithelial cells against oxidative damage and delay or inhibit the development and generation of glucose-induced renal insufficiency at the early stage of disease."( Pyridoxamine Treatment of HK-2 Human Proximal Tubular Epithelial Cells Reduces Oxidative Stress and the Inhibition of Autophagy Induced by High Glucose Levels.
Chang, J; Chi, Y; Han, N; Li, Y; Wang, Y; Wang, Z; Yang, Z; Zhang, T; Zhao, K, 2019
)
2.68
"Pyridoxamine (PM) has long been known to inhibit protein glycation via various mechanisms of action. "( A comparative study of the chemical reactivity of pyridoxamine, Ac-Phe-Lys and Ac-Cys with various glycating carbonyl compounds.
Adrover, M; Donoso, J; Frau, J; Muñoz, F; Vilanova, B, 2009
)
2.05

Actions

ExcerptReferenceRelevance
"Pyridoxamine was found to suppress weight increases and M1 polarization, and to increase Glo-1 expression through the RAGE pathway in perivascular and visceral fat tissues of HFD-induced obese rats."( The attenuating effects of pyridoxamine on adipocyte hypertrophy and inflammation differ by adipocyte location.
Ahn, H; Byun, K; Hwang, D; Lee, JI; Lee, S; Oh, S; Park, H; Park, KY; Son, KH, 2019
)
1.53

Treatment

Pyridoxamine treatment was associated with increased levels of tumor necrosis factor alpha (TNF-α) mRNA transcripts in the liver. Treatment resulted in significantly lower levels of urinary glycolate and oxalate excretion compared to untreated hyperoxaluric animals.

ExcerptReferenceRelevance
"Pyridoxamine treatment prevents large artery stiffening with advancing age, but the effects of pyridoxamine treatment on the cerebral vasculature or cognition is unknown."( Pyridoxamine treatment ameliorates large artery stiffening and cerebral artery endothelial dysfunction in old mice.
Colton Bramwell, R; Cullen, AE; Henson, GD; Khurana, A; Kronquist, EK; Lee, B; Machin, DR; Meza, A; Peterson, JA; Pham, H; Reeve, EH; Villasana, L; Walker, AE; Wolf, JR, 2023
)
3.07
"Pyridoxamine treatment was associated with increased levels of tumor necrosis factor alpha (TNF-α) mRNA transcripts in the liver."( Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease.
Daliry, A; Flores, EEI; Pereira, ENGDS; Rodrigues, KL; Silvares, RR, 2020
)
2.72
"Pyridoxamine treatment also prevented the loss in secondary structure induced by glycation."( Study of pyridoxamine against glycation and reactive oxygen species production in human serum albumin as model protein: An in vitro & ex vivo approach.
Abdullah, KM; Ahmad, I; Hasan, H; Naseem, I; Qais, FA, 2018
)
1.62
"Pyridoxamine treatment decreased glycation and restored the activation of JNK and Akt during ischemia."( Pyridoxamine reverts methylglyoxal-induced impairment of survival pathways during heart ischemia.
Almeida, F; Crisóstomo, J; Gonçalves, L; Matafome, P; Rodrigues, T; Santos-Silva, D; Seiça, R; Sena, C, 2013
)
2.55
"Pyridoxamine treatment resulted in significantly lower (by approximately 50%) levels of urinary glycolate and oxalate excretion compared to untreated hyperoxaluric animals. "( Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Belmont, JM; Chetyrkin, SV; Hudson, BG; Kim, D; Scheinman, JI; Voziyan, PA, 2005
)
3.21
"Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions."( Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F, 2006
)
1.06
"Pyridoxamine treatment did not restore erythrocyte glutathione (which was reduced by almost half) in diabetic animals, but it enhanced erythrocyte glyoxalase I activity."( Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal.
Biemel, KM; Lederer, MO; Mally, A; Nagaraj, RH; Padayatti, PS; Sarkar, P, 2002
)
1.44
"Treatment with pyridoxamine (an inhibitor of advanced glycation end-products) may represent a strategy to counter these injurious pathways."( Have we reached the limits for the treatment of diabetic nephropathy?
Goldsmith, DJ; Hajhosseiny, R; Jivraj, N; Khavandi, K; Malik, RA; Mashayekhi, S, 2014
)
0.74

Toxicity

ExcerptReferenceRelevance
" These findings suggest that UVA-induced vitamin B6 cytotoxicity is caused by toxic photoproducts resulting from irradiated vitamin B6."( Vitamin B6 phototoxicity induced by UVA radiation.
Kosaka, H; Maeda, T; Minami, H; Sato, K; Shiga, T; Taguchi, H; Yoshikawa, K, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma clearance and volume of distribution of PLP decreased significantly after supplementation, but half-life t 1/2 did not change."( Relationship between body store of vitamin B6 and plasma pyridoxal-P clearance: metabolic balance studies in humans.
Aronoff, GR; Li, TK; Lui, A; Lumeng, L, 1985
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" By contrast, renal damage was aggravated when PM was combined with ACEi."( Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
Navis, G; van Goor, H; Waanders, F, 2008
)
0.61

Bioavailability

ExcerptReferenceRelevance
"Intraluminal perfusion of human jejunum has not been previously reported to demonstrate differences in bioavailability of vitamins from a food product."( Comparative human intestinal bioavailability of vitamin B-6 from a synthetic and a natural source.
Cerda, JJ; Lane, H; Nelson, EW, 1976
)
0.26
" Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed."( The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes.
Crisóstomo, J; Fernandes, R; Pereira, A; Seiça, RM; Sena, CM, 2017
)
0.77

Dosage Studied

ExcerptRelevanceReference
" brevis responded equally to all three free forms of vitamin B-6 at a dosage range of 2--10 ng molar equivalent of pyridoxine."( Growth response of the yeasts Saccharomyces uvarum and Kloeckera brevis to the free biologically active forms of vitamin B-6.
Guilarte, TR; McIntyre, PA; Tsan, MF, 1980
)
0.26
" In comparison with pyridoxal, pyridoxine, and ascorbic acid, PM exerted the highest inhibition activity against AA formation, and a clear dose-response was observed."( Effect of pyridoxamine on acrylamide formation in a glucose/asparagine model system.
Arribas-Lorenzo, G; Morales, FJ, 2009
)
0.76
" Our goal was to exploit the food supplements to mimic the topical antivirals' functions but circumventing their severe side effects, which has limited the necessary dosage needed to exhibit the desired antiviral activity."( Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19.
Aghamohammadi, M; França, TCC; Goncalves, AS; LaPlante, SR; Shahdousti, P; Sirouspour, M, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
iron chelatornull
nephroprotective agentAny protective agent that is able to prevent damage to the kidney.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
hydroxymethylpyridineAny member of the class of pyridines carrying a hydroxymethyl substituent at unspecified position.
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
aminoalkylpyridine
vitamin B6Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Vitamin B6 activation to pyridoxal phosphate318
Vitamin B6 Metabolism515
Hypophosphatasia515
Vitamin B6228
Vitamin B6 metabolism ( Vitamin B6 metabolism )417
pyridoxamine anabolism08
Superpathway of pyridoxal 5'-phosphate biosynthesis and salvage014
Pyridoxal 5'-phosphate salvage pathway112
Pyridoxamine anabolism17

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.58930.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.44670.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyridoxal kinaseHomo sapiens (human)Km130.00005.00007.45009.9000AID464423
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
pyridoxal 5'-phosphate salvagePyridoxal kinaseHomo sapiens (human)
pyridoxal metabolic processPyridoxal kinaseHomo sapiens (human)
pyridoxamine metabolic processPyridoxal kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyridoxal kinaseHomo sapiens (human)
ATP bindingPyridoxal kinaseHomo sapiens (human)
zinc ion bindingPyridoxal kinaseHomo sapiens (human)
pyridoxal kinase activityPyridoxal kinaseHomo sapiens (human)
pyridoxal phosphate bindingPyridoxal kinaseHomo sapiens (human)
potassium ion bindingPyridoxal kinaseHomo sapiens (human)
sodium ion bindingPyridoxal kinaseHomo sapiens (human)
lithium ion bindingPyridoxal kinaseHomo sapiens (human)
protein homodimerization activityPyridoxal kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionPyridoxal kinaseHomo sapiens (human)
nucleusPyridoxal kinaseHomo sapiens (human)
nucleoplasmPyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
secretory granule lumenPyridoxal kinaseHomo sapiens (human)
specific granule lumenPyridoxal kinaseHomo sapiens (human)
extracellular exosomePyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID450165Cytoprotective activity against MG-induced cytotoxicity in human EAhy926 cells assessed as viable cells at 1 mM after overnight incubation by MTT assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID626542Inhibition of Cu2-amyloid beta (1 to 20) complex-induced dopamine oxidation by spectrophotometry2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related Cu(II)-β-amyloid complexes-cooperative action of phospho-moiety.
AID464423Activity at human PKH kinase expressed in Escherichia coli by affinity chromatography2010Journal of natural products, Jan, Volume: 73, Issue:1
Ginkgo biloba and ginkgotoxin.
AID626543Competitive inhibition of full-length Cu2-amyloid beta (1 to 40) complex-induced dopamine oxidation by Lineweaver-Burk plot analysis2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related Cu(II)-β-amyloid complexes-cooperative action of phospho-moiety.
AID450158Inhibition of alpha-dicarbonyls-induced advanced glycation end product formation assessed as protection against 50 eq. MG-induced insulin degradation at 3.75 mM after 24 hrs by RP-HPLC2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID626540Inhibition of Cu2-amyloid beta (1 to 16) complex-induced dopamine oxidation by spectrophotometry2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related Cu(II)-β-amyloid complexes-cooperative action of phospho-moiety.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID450166Cytotoxicity in human EAhy926 cells assessed as viable cells at 1 mM after overnight incubation by MTT assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID626541Inhibition of Cu2-amyloid beta (1 to 40) complex-induced dopamine oxidation by spectrophotometry2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related Cu(II)-β-amyloid complexes-cooperative action of phospho-moiety.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (636)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990267 (41.98)18.7374
1990's72 (11.32)18.2507
2000's137 (21.54)29.6817
2010's129 (20.28)24.3611
2020's31 (4.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (1.34%)5.53%
Reviews51 (7.59%)6.00%
Case Studies1 (0.15%)4.05%
Observational0 (0.00%)0.25%
Other611 (90.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2b Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Nephropathy Due to Type 2 Diabetes [NCT00734253]Phase 2317 participants (Actual)Interventional2008-08-31Completed
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER) [NCT02156843]Phase 3328 participants (Actual)Interventional2014-06-30Terminated
Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria [NCT00490113]Phase 20 participants (Actual)Interventional2007-01-31Withdrawn(stopped due to Drug unavailable)
The Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity; a Double-blind Randomized Placebo Controlled Trial in Abdominally Obese Subjects. [NCT02954588]112 participants (Actual)Interventional2016-10-14Completed
Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes Treated With Pyridoxamine [NCT03778580]55 participants (Actual)Interventional2018-03-01Completed
A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diab [NCT00320021]Phase 280 participants Interventional2002-07-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes [NCT00320060]Phase 2128 participants Interventional2001-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]